322 related articles for article (PubMed ID: 28790158)
21. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
[TBL] [Abstract][Full Text] [Related]
22. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
Lee JW; Zhang Y; Eoh KJ; Sharma R; Sanmamed MF; Wu J; Choi J; Park HS; Iwasaki A; Kaftan E; Chen L; Papadimitrakopoulou V; Herbst RS; Koo JS
J Thorac Oncol; 2019 Jun; 14(6):1046-1060. PubMed ID: 30771521
[TBL] [Abstract][Full Text] [Related]
23. Potential Predictive Value of
Dong ZY; Zhong WZ; Zhang XC; Su J; Xie Z; Liu SY; Tu HY; Chen HJ; Sun YL; Zhou Q; Yang JJ; Yang XN; Lin JX; Yan HH; Zhai HR; Yan LX; Liao RQ; Wu SP; Wu YL
Clin Cancer Res; 2017 Jun; 23(12):3012-3024. PubMed ID: 28039262
[No Abstract] [Full Text] [Related]
24. Ercc1 Deficiency Promotes Tumorigenesis and Increases Cisplatin Sensitivity in a Tp53 Context-Specific Manner.
Jokić M; Vlašić I; Rinneburger M; Klümper N; Spiro J; Vogel W; Offermann A; Kümpers C; Fritz C; Schmitt A; Riabinska A; Wittersheim M; Michels S; Ozretić L; Florin A; Welcker D; Akyuz MD; Nowak M; Erkel M; Wolf J; Büttner R; Schumacher B; Thomale J; Persigehl T; Maintz D; Perner S; Reinhardt HC
Mol Cancer Res; 2016 Nov; 14(11):1110-1123. PubMed ID: 27514406
[TBL] [Abstract][Full Text] [Related]
25. Statin as anti-cancer therapy in autochthonous T-lymphomas expressing stabilized gain-of-function mutant p53 proteins.
Tutuska K; Parrilla-Monge L; Di Cesare E; Nemajerova A; Moll UM
Cell Death Dis; 2020 Apr; 11(4):274. PubMed ID: 32332697
[TBL] [Abstract][Full Text] [Related]
26. Mutant p53(R270H) gain of function phenotype in a mouse model for oncogene-induced mammary carcinogenesis.
Heinlein C; Krepulat F; Löhler J; Speidel D; Deppert W; Tolstonog GV
Int J Cancer; 2008 Apr; 122(8):1701-9. PubMed ID: 18092324
[TBL] [Abstract][Full Text] [Related]
27. Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.
Juchum M; Günther M; Laufer SA
Drug Resist Updat; 2015 May; 20():12-28. PubMed ID: 26021435
[TBL] [Abstract][Full Text] [Related]
28. Synergistic and additive effect of retinoic acid in circumventing resistance to p53 restoration.
Larsson CA; Moyer SM; Liu B; Michel KA; Pant V; Yang P; Wong J; El-Naggar AK; Krahe R; Lozano G
Proc Natl Acad Sci U S A; 2018 Feb; 115(9):2198-2203. PubMed ID: 29440484
[No Abstract] [Full Text] [Related]
29. Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets.
Drosten M; Barbacid M
J Mol Med (Berl); 2016 Feb; 94(2):121-35. PubMed ID: 26526121
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of MAGEA2 has a prognostic significance and is a potential therapeutic target for patients with lung cancer.
Ujiie H; Kato T; Lee D; Hu HP; Fujino K; Kaji M; Kaga K; Matsui Y; Yasufuku K
Int J Oncol; 2017 Jun; 50(6):2154-2170. PubMed ID: 28498455
[TBL] [Abstract][Full Text] [Related]
31. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
[TBL] [Abstract][Full Text] [Related]
32. Spindle Assembly Checkpoint Inhibition Can Resensitize p53-Null Stem Cells to Cancer Chemotherapy.
Liu C; Banister CE; Buckhaults PJ
Cancer Res; 2019 May; 79(9):2392-2403. PubMed ID: 30862715
[TBL] [Abstract][Full Text] [Related]
33. Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas.
Lee TF; Tseng YC; Nguyen PA; Li YC; Ho CC; Wu CW
Sci Rep; 2018 Jan; 8(1):271. PubMed ID: 29321482
[TBL] [Abstract][Full Text] [Related]
34. An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations.
Caulin C; Nguyen T; Lang GA; Goepfert TM; Brinkley BR; Cai WW; Lozano G; Roop DR
J Clin Invest; 2007 Jul; 117(7):1893-901. PubMed ID: 17607363
[TBL] [Abstract][Full Text] [Related]
35. The lung-enriched p53 mutants V157F and R158L/P regulate a gain of function transcriptome in lung cancer.
Barta JA; Pauley K; Kossenkov AV; McMahon SB
Carcinogenesis; 2020 Mar; 41(1):67-77. PubMed ID: 31067569
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells.
Valente LJ; Aubrey BJ; Herold MJ; Kelly GL; Happo L; Scott CL; Newbold A; Johnstone RW; Huang DC; Vassilev LT; Strasser A
Cell Rep; 2016 Mar; 14(8):1858-66. PubMed ID: 26904937
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas.
Jin Y; Shi X; Zhao J; He Q; Chen M; Yan J; Ou Q; Wu X; Shao YW; Yu X
Lung Cancer; 2018 Oct; 124():110-116. PubMed ID: 30268447
[TBL] [Abstract][Full Text] [Related]
38. Comparison of effects of p53 null and gain-of-function mutations on salivary tumors in MMTV-Hras transgenic mice.
Jiang D; Dumur CI; Massey HD; Ramakrishnan V; Subler MA; Windle JJ
PLoS One; 2015; 10(2):e0118029. PubMed ID: 25695772
[TBL] [Abstract][Full Text] [Related]
39. Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors.
Balko JM; Potti A; Saunders C; Stromberg A; Haura EB; Black EP
BMC Genomics; 2006 Nov; 7():289. PubMed ID: 17096850
[TBL] [Abstract][Full Text] [Related]
40. A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapy.
Cannell IG; Merrick KA; Morandell S; Zhu CQ; Braun CJ; Grant RA; Cameron ER; Tsao MS; Hemann MT; Yaffe MB
Cancer Cell; 2015 Nov; 28(5):623-637. PubMed ID: 26602816
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
